Can bone scans guide therapy with radium-223 dichloride for prostate cancer bone metastases?
Isis Gayed,1 Vivian Salama,2 Lydia Dawood,1 Steven Canfield,3 David Wan,1 Chunyan Cai,4 Usha Joseph,1 Robert Amato5 1Nuclear Medicine Section, Department of Diagnostic and Interventional Imaging, University of Texas Health Science Center at Houston, 2Graduate School of Biomedical Sciences, Universit...
Main Authors: | Gayed I, Salama V, Dawood L, Canfield S, Wan D, Cai C, Joseph U, Amato R |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2018-09-01
|
Series: | Cancer Management and Research |
Subjects: | |
Online Access: | https://www.dovepress.com/can-bone-scans-guide-therapy-with-radium-223-dichloride-for-prostate-c-peer-reviewed-article-CMAR |
Similar Items
-
Radium-223 in metastatic castration resistant prostate cancer
by: Winston Vuong, et al.
Published: (2014-06-01) -
Retrospective Toxicological Profiling of Radium-223 Dichloride for the Treatment of Bone Metastases in Prostate Cancer Using Adverse Event Data
by: Theodoros G. Soldatos, et al.
Published: (2019-05-01) -
Radium-223-Dichloride in Castration Resistant Metastatic Prostate Cancer—Preliminary Results of the Response Evaluation Using F-18-Fluoride PET/CT
by: Kalevi Kairemo, et al.
Published: (2015-10-01) -
Dynamic changes of bone metastasis predict bone‐predominant status to benefit from radium‐223 dichloride for patients with castration‐resistant prostate cancer
by: Kohei Hashimoto, et al.
Published: (2020-11-01) -
Bone pain palliation outcomes and possibility of Radium-223 re-treatment in mCRPC
by: Viviana Frantellizzi, et al.
Published: (2020-10-01)